Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP732109.RAly40k3Bi5eLNxGrhC27xP5fc7drNs7GD_E-b-vnpZgU130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP732109.RAly40k3Bi5eLNxGrhC27xP5fc7drNs7GD_E-b-vnpZgU130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP732109.RAly40k3Bi5eLNxGrhC27xP5fc7drNs7GD_E-b-vnpZgU130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP732109.RAly40k3Bi5eLNxGrhC27xP5fc7drNs7GD_E-b-vnpZgU130_provenance.
- befree-2016 importedOn "2016-02-19" NP732109.RAly40k3Bi5eLNxGrhC27xP5fc7drNs7GD_E-b-vnpZgU130_provenance.
- NP732109.RAly40k3Bi5eLNxGrhC27xP5fc7drNs7GD_E-b-vnpZgU130_assertion wasGeneratedBy ECO_0000203 NP732109.RAly40k3Bi5eLNxGrhC27xP5fc7drNs7GD_E-b-vnpZgU130_provenance.
- NP732109.RAly40k3Bi5eLNxGrhC27xP5fc7drNs7GD_E-b-vnpZgU130_assertion wasDerivedFrom befree-2016 NP732109.RAly40k3Bi5eLNxGrhC27xP5fc7drNs7GD_E-b-vnpZgU130_provenance.
- NP732109.RAly40k3Bi5eLNxGrhC27xP5fc7drNs7GD_E-b-vnpZgU130_assertion SIO_000772 19363496 NP732109.RAly40k3Bi5eLNxGrhC27xP5fc7drNs7GD_E-b-vnpZgU130_provenance.
- NP732109.RAly40k3Bi5eLNxGrhC27xP5fc7drNs7GD_E-b-vnpZgU130_assertion evidence source_evidence_literature NP732109.RAly40k3Bi5eLNxGrhC27xP5fc7drNs7GD_E-b-vnpZgU130_provenance.
- NP732109.RAly40k3Bi5eLNxGrhC27xP5fc7drNs7GD_E-b-vnpZgU130_assertion description "[Our method can quantify amounts of MYC oncoprotein and B cell lymphoma protein-2 (BCL2) in Burkitt's and follicular lymphoma; identify changes in activation of extracellular signal-related kinases-1 (ERK1) and ERK2, mitogen-activated kinase-1 (MEK), signal transducer and activator of transcription protein-3 (STAT3) and STAT5, c-Jun N-terminal kinase (JNK) and caspase-3 in imatinib-treated chronic myelogeneous leukemia (CML) cells; measure an unanticipated change in the phosphorylation of an ERK2 isomer in individuals with CML who responded to imatinib; and detect a decrease in STAT3 and STAT5 phosphorylation in individuals with lymphoma who were treated with atorvastatin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP732109.RAly40k3Bi5eLNxGrhC27xP5fc7drNs7GD_E-b-vnpZgU130_provenance.